Replication-defective canarypox (ALVAC) vectors effectively activate anti-human immunodeficiency virus-1 cytotoxic T lymphocytes present in infected patients: implications for antigen-specific immunotherapy

In the attempt to develop immunotherapeutic strategies for acquired immunodeficiency syndrome capable of activating effector cells in an antigen-specific manner while maintaining the broadest possible T-cell repertoire, we evaluated two canarypox (ALVAC)-based vectors for their capacity to induce ex vivo activation/expansion of human immunodeficiency virus (HIV)-specific CD8+ cytotoxic lymphocyte precursors (CTLp) obtained from HIV-1-infected donors. These two vectors, vCP205 encoding HIV-1 gp120 + TM (28 amino acid transmembrane anchor sequence) in addition to Gag/protease and vCP300 encoding gp120 + Gag/protease as well as Nef and Pol CTL determinants, are pancytotropic but replication incompetent in mammalian cells. Bulk peripheral blood mononuclear cells (PBMCs) or enriched CD8+ T cells were stimulated for 10 days with autologous ALVAC-infected PBMCs in the presence of different cytokine combinations (interleukin-2 [IL-2], IL-4, IL-7, and IL-12). Activation by ALVAC constructs was highly antigen-specific, because vCP205 elicited only Env and Gag CTL, whereas vCP300 elicited broader reactivities against Env, Gag, Pol, and Nef determinants. The ALVAC activation of CTLp was IL-2 dependent and enhanced by the addition of IL-7, whereas IL-4 and IL-12 failed to augment cytotoxic reactivities elicited by these constructs. The expansion of enriched CD8+ T cells after activation with vCP300 was higher in patients with CD4 counts greater than 400 cells/microL. Two rounds of in vitro stimulation (IVS) with vCP300 resulted in nearly an eightfold expansion of CD8+ lymphocytes over a 25-day period. After the second IVS, an average 3.2-fold increase among the different antigen-specific CTL frequencies was achieved. These studies clearly show that HIV-recombinant ALVAC vectors represent powerful polyvalent antigenic stimuli for activation and expansion of the CD8 lymphocyte response that occurs as a result of HIV infection.

[1]  R P Johnson,et al.  Suppression of human immunodeficiency virus type 1 replication by CD8+ cells: evidence for HLA class I-restricted triggering of cytolytic and noncytolytic mechanisms , 1997, Journal of virology.

[2]  Marc Parmentier,et al.  A Dual-Tropic Primary HIV-1 Isolate That Uses Fusin and the β-Chemokine Receptors CKR-5, CKR-3, and CKR-2b as Fusion Cofactors , 1996, Cell.

[3]  Ying Sun,et al.  The β-Chemokine Receptors CCR3 and CCR5 Facilitate Infection by Primary HIV-1 Isolates , 1996, Cell.

[4]  Virginia Litwin,et al.  HIV-1 entry into CD4+ cells is mediated by the chemokine receptor CC-CKR-5 , 1996, Nature.

[5]  Stephen C. Peiper,et al.  Identification of a major co-receptor for primary isolates of HIV-1 , 1996, Nature.

[6]  G. Ferrari,et al.  Oligoclonal CD8 lymphocytes from persons with asymptomatic human immunodeficiency virus (HIV) type 1 infection inhibit HIV-1 replication. , 1995, The Journal of infectious diseases.

[7]  R. Siliciano,et al.  Induction of human immunodeficiency virus type 1 (HIV-1)-specific cytolytic T lymphocyte responses in seronegative adults by a nonreplicating, host-range-restricted canarypox vector (ALVAC) carrying the HIV-1MN env gene. , 1995, The Journal of infectious diseases.

[8]  E. Paoletti,et al.  HIV-1 recombinant poxvirus vaccine induces cross-protection against HIV-2 challenge in rhesus macaques , 1995, Nature Medicine.

[9]  H. Clifford Lane,et al.  Transfer of HIV-1-specific cytotoxic T lymphocytes to an AIDS patient leads to selection for mutant HIV variants and subsequent disease progression , 1995, Nature Medicine.

[10]  H. Schuitemaker,et al.  Kinetics of Gag-specific cytotoxic T lymphocyte responses during the clinical course of HIV-1 infection: a longitudinal analysis of rapid progressors and long-term asymptomatics , 1995, The Journal of experimental medicine.

[11]  J. Levy,et al.  CD8+ T cells suppress human immunodeficiency virus replication by inhibiting viral transcription. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[12]  S. Rowland-Jones,et al.  HIV-specific cytotoxic T-cells in HIV-exposed but uninfected Gambian women , 1995, Nature Medicine.

[13]  J. Lieberman,et al.  Ex vivo expansion of HIV type 1-specific cytolytic T cells from HIV type 1-seropositive subjects. , 1995, AIDS research and human retroviruses.

[14]  A. Perelson,et al.  Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection , 1995, Nature.

[15]  Martin A. Nowak,et al.  Viral dynamics in human immunodeficiency virus type 1 infection , 1995, Nature.

[16]  G. Trinchieri,et al.  Interleukin-12: a cytokine produced by antigen-presenting cells with immunoregulatory functions in the generation of T-helper cells type 1 and cytotoxic lymphocytes. , 1994, Blood.

[17]  C. Carini,et al.  Dysregulation of interleukin‐7 receptor may generate loss of cytotoxic T cell response in human immunodeficiency virus type 1 infection , 1994, European journal of immunology.

[18]  G. Shaw,et al.  Virus-specific CD8+ cytotoxic T-lymphocyte activity associated with control of viremia in primary human immunodeficiency virus type 1 infection , 1994, Journal of virology.

[19]  D. Ho,et al.  Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome , 1994, Journal of virology.

[20]  F. Erard,et al.  Non-cytotoxic, IL-4, IL-5, IL-10 producing CD8+ T cells: their activation and effector functions. , 1994, Current opinion in immunology.

[21]  M. Croft.  Activation of naive, memory and effector T cells. , 1994, Current opinion in immunology.

[22]  C. Carini,et al.  Interleukin 2-independent interleukin 7 activity enhances cytotoxic immune response of HIV-1-infected individuals. , 1994, AIDS research and human retroviruses.

[23]  J. Bartlett,et al.  CD8+ T lymphocyte-mediated inhibition of HIV-1 long terminal repeat transcription: a novel antiviral mechanism. , 1993, AIDS research and human retroviruses.

[24]  J. Siegel,et al.  Effects of IL-12 on the generation of cytotoxic activity in human CD8+ T lymphocytes. , 1993, Journal of immunology.

[25]  E. Paoletti,et al.  Induction of cytotoxic T lymphocytes by recombinant canarypox (ALVAC) and attenuated vaccinia (NYVAC) viruses expressing the HIV-1 envelope glycoprotein. , 1993, Virology.

[26]  M. Perkus,et al.  Methodology of using vaccinia virus to express foreign genes in tissue culture , 1993 .

[27]  Phalguni Gupta,et al.  Generation and characterization of ex vivo propagated autologous CD8+ cells used for adoptive immunotherapy of patients infected with human immunodeficiency virus , 1993 .

[28]  C. Rinaldo,et al.  A phase 1 study of adoptive transfer of autologous CD8+ T lymphocytes in patients with acquired immunodeficiency syndrome (AIDS)-related complex or AIDS. , 1993, Blood.

[29]  S. Rowland-Jones,et al.  HIV-specific cytotoxic T-cell activity in an HIV-exposed but uninfected infant , 1993, The Lancet.

[30]  E. Paoletti,et al.  Protection of cats against feline leukemia virus by vaccination with a canarypox virus recombinant, ALVAC-FL , 1993, Journal of virology.

[31]  J. Giorgi,et al.  Circulating HIV-specific CD8+ cytotoxic T cells express CD38 and HLA-DR antigens. , 1993, Journal of immunology.

[32]  Anthony S. Fauci,et al.  HIV infection is active and progressive in lymphoid tissue during the clinically latent stage of disease , 1993, Nature.

[33]  Ashley T. Haase,et al.  Massive covert infection of helper T lymphocytes and macrophages by HIV during the incubation period of AIDS , 1993, Nature.

[34]  X. Jin,et al.  Quantitative analysis of the human immunodeficiency virus type 1 (HIV- 1)-specific cytotoxic T lymphocyte (CTL) response at different stages of HIV-1 infection: differential CTL responses to HIV-1 and Epstein- Barr virus in late disease , 1993, The Journal of experimental medicine.

[35]  M. Lotze,et al.  Use of T-Cell Growth Factors (Interleukins 2, 4, 7, 10, and 12) in the Evaluation of T-Cell Reactivity to Melanoma , 1992, Journal of immunotherapy : official journal of the Society for Biological Therapy.

[36]  C. Griscelli,et al.  Cytotoxic T lymphocyte responses in the peripheral blood of children born to human immunodeficiency virus‐1‐infected mothers , 1992, European journal of immunology.

[37]  M. Perkus,et al.  Highly attenuated poxvirus vectors. , 1992, AIDS research and human retroviruses.

[38]  E. Paoletti,et al.  Specific activation strategies for amplification of low CTL signals. , 1992, AIDS research and human retroviruses.

[39]  S. Riddell,et al.  Restoration of viral immunity in immunodeficient humans by the adoptive transfer of T cell clones. , 1992, Science.

[40]  E. Paoletti,et al.  Immunisation with canarypox virus expressing rabies glycoprotein , 1992, The Lancet.

[41]  B. Pogo,et al.  Stimulation of lymphokines in Jurkat cells persistently infected with vaccinia virus , 1992, Journal of virology.

[42]  Robert E. Miller,et al.  In vivo evaluation of the effects of interleukins 2, 4 and 7 on enhancing the immunotherapeutic efficacy of anti‐tumor cytotoxic T lymphocytes , 1991, European journal of immunology.

[43]  R. Koup,et al.  Limiting dilution analysis of cytotoxic T lymphocytes to human immunodeficiency virus gag antigens in infected persons: in vitro quantitation of effector cell populations with p17 and p24 specificities , 1991, The Journal of experimental medicine.

[44]  D. Nixon,et al.  Cytotoxic T-cell recognition of HIV proteins and peptides. , 1991, AIDS.

[45]  A. Fauci,et al.  Immunopathogenic mechanisms in human immunodeficiency virus (HIV) infections. , 1991, Annals of the New York Academy of Sciences.

[46]  D. Loh,et al.  Receptor-stimulated death pathway is opened by antigen in mature T cells. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[47]  P. Kinchington,et al.  Equivalent recognition of a varicella-zoster virus immediate early protein (IE62) and glycoprotein I by cytotoxic T lymphocytes of either CD4+ or CD8+ phenotype. , 1991, Journal of immunology.

[48]  G. Rutherford,et al.  Course of HIV-I infection in a cohort of homosexual and bisexual men: an 11 year follow up study. , 1990, BMJ.

[49]  B. Moss,et al.  CD8+ T lymphocytes of patients with AIDS maintain normal broad cytolytic function despite the loss of human immunodeficiency virus-specific cytotoxicity. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[50]  S. Goebel,et al.  Newcastle disease virus fusion protein expressed in a fowlpox virus recombinant confers protection in chickens , 1990, Journal of virology.

[51]  D. Tyler,et al.  Minireview Anti-HIV-1 ADCC , 1989 .

[52]  M. Perkus,et al.  Cloning and expression of foreign genes in vaccinia virus, using a host range selection system , 1989, Journal of virology.

[53]  J. Levy,et al.  A diffusible lymphokine produced by CD8+ T lymphocytes suppresses HIV replication. , 1989, Immunology.

[54]  W. Darrow,et al.  Risk of developing AIDS in HIV-infected cohorts of hemophilic and homosexual men. , 1989, JAMA.

[55]  D. Horohov,et al.  IL-4 (B cell-stimulatory factor 1) regulates multiple aspects of influenza virus-specific cell-mediated immunity. , 1988, Journal of immunology.

[56]  M. Reitz,et al.  Envelope sequences of two new United States HIV-1 isolates. , 1988, Virology.

[57]  T. S. Jones,et al.  Disseminated vaccinia in a military recruit with human immunodeficiency virus (HIV) disease. , 1987, The New England journal of medicine.

[58]  J. Levy,et al.  CD8+ lymphocytes can control HIV infection in vitro by suppressing virus replication. , 1986, Science.

[59]  Mark L. Pearson,et al.  Complete nucleotide sequence of the AIDS virus, HTLV-III , 1985, Nature.

[60]  A. McMichael,et al.  Cytotoxic T-cell immunity to influenza. , 1983, The New England journal of medicine.